Professor Carl Clarke

Professor of Clinical Neurology

Neurobiology

Clarke,Carl-Cropped-110x146

Contact details

Telephone +44 (0)121 507 4073

Fax +44 (0)121 507 5442

Email c.e.clarke@bham.ac.uk

School of Clinical and Experimental Medicine
College of Medical and Dental Sciences

About

Professor Clarke has a long history of research in Parkinson's disease and headache disorders. He is currently running several large pragmatic clinical trials examining medical, surgical and rehabilitation interventions in Parkinson's disease (PD MED, PD SURG, PD REHAB, PD COMM and PD GEN).

Qualifications

  • FRCP
  • MD
  • MB ChB
  • BSc

Teaching

  • Instigator and co-ordinator of third year medical student Neurology Demonstration Programme
  • Instigator and co-ordinator of Birmingham Movement Disorders Course
  • Regular clinical teaching to all clinical medical student years
  • Lecturer on Good Brain-Bad Brain Course

Postgraduate supervision

Both MD and PhD Students.

Research

Professor Clarke has performed a wide variety of research work in Parkinson's disease over the last 15 years. This includes work on the MPTP primate model of the condition, examination of several potential diagnostic tests, systematic reviews of clinical trials in Parkinson's disease, and work on the effects of Parkinson's disease on quality of life and health economics. He is currently leading large pragmatic clinical trials examining medical, surgical and rehabilitation interventions in the condition (PD MED, PD SURG, PD REHAB and PD GEN). He was also the clinical advisor to the Technical Team preparing the NICE Parkinson's disease guidelines.

Other activities

  • Director of Research and Development, Sandwell and West Birmingham Hospitals NHS Trust.
  • Movement Disorders, headache and general neurology clinics at City Hospital, Birmingham, Sandwell and West Birmingham Hospitals NHS Trust.

Publications

Stowe R, Ives N, Clarke CE, Deane K, van Hilten, Wheatley K, Gray R, Handley K, Furmston A. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD007166. DOI: 10.1002/14651858.CD007166.pub2.

Clarke CE, Edwards J, Nicholl DJ, Sivaguru A. Imaging results in a consecutive series of 530 new patients in the Birmingham Headache Service. J Neurol 2010;1274-78.

Lambert TD, Morrison KE, Edwards J, Clarke CE. The use of complementary and alternative medicine by patients attending a UK headache clinic. Complementary Therapies in Medicine 2010;18:128-134.

Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, Jacks A, Lawden M, Clarke CE, Stewart PM, Walker EA, Tomlinson JW, Rauz S. Low calorie diet and intracranial pressure in idiopathic intracranial hypertension: prospective cohort study. BMJ 2010;341:c2701.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Disorder 2010;25:2649-53.

Clarke CE. Has drug therapy changed the natural history of Parkinson’s disease? Journal of Neurology 2010;257 (suppl 2):S262-7.

Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, Barker RA, Bellenguez C, Bhatia K, Blackburn H, et al: Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics 2011;20:345-353.

International Parkinson's Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 2011. DOI:10.1016/S0140-6736(10)62345-8.

Back to top